The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic
Authors:
- 10 February 2016
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 32 (4) , 779-785
Abstract
Aims: To examine the long-term persistence and safety of the non-vitamin K antagonist oral anticoagulants (NOAC); dabigatran (D), rivaroxaban (R) and apixaban (A) in patients with non-valvular atrial fibrillation (AF) treated in the framework of a well-structured, nurse-based AF unit for initiation and follow-up of NOAC.Methods: Retrospective clinical data were collected for 766 consequent patients from a single cardiology outpatient clinic incorporating the AF unit.Results: The follow-up time was 367 days (183-493) for D patients, 432 days (255-546) for R patients and 348 days (267-419) for A patients. No significant differences were found between the three groups in regards to age, sex, renal function, or CHA2DS2-VASc score. For all bleeding events the incidence rates per 100 patient-years of follow-up (95% Confidence Interval (CI), p-value) were reported more often for treatment with R (17.2, 12.7-22.8) than for D (7.0, 4.0 - 11.3, p=0.001), and A (8.7, 5.2-13.6, p=0.013). The differences remai...Keywords
This publication has 17 references indexed in Scilit:
- Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillationThrombosis and Haemostasis, 2015
- Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinicInternational Journal Of Clinical Practice, 2015
- Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registryEP Europace, 2015
- Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial FibrillationCirculation, 2015
- EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary†European Heart Journal, 2013
- Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial FibrillationCirculation, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005